Question 1

What specific treatments will I receive if I participate in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer clinical trial (NCT05977036). Contact the study team or your healthcare provider for specific answers.

Question 2

How will my blood test results affect my treatment plan?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer clinical trial (NCT05977036). Contact the study team or your healthcare provider for specific answers.

Question 3

What are the potential side effects of the CDK4/6 inhibitor and endocrine therapy?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer clinical trial (NCT05977036). Contact the study team or your healthcare provider for specific answers.

Question 4

How often will I need to come in for visits and tests during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer clinical trial (NCT05977036). Contact the study team or your healthcare provider for specific answers.

Question 5

What happens if my blood test shows a lack of TKa suppression?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer clinical trial (NCT05977036). Contact the study team or your healthcare provider for specific answers.

Question 6

How does this trial compare to other treatment options available to me?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer clinical trial (NCT05977036). Contact the study team or your healthcare provider for specific answers.

What this study is about